世界のメタボリックシンドローム市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global Metabolic Syndrome Market Size, Status and Forecast 2021-2027

• レポートコード：QFJ1-4493 • 出版社/出版日：QYResearch / 2021年6月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、120ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療

• 販売価格（消費税別）

Single User	￥577,200 (USD3,900)	▷ お問い合わせ
Multi User	￥865,800 (USD5,850)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

QYResearch社発行の本調査レポートでは、メタボリックシンドロームの世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（糖尿病、肥満、高コレステロール血症、リソソーム蓄積症）、用途別市場規模（病院、クリニック、その他）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、企業情報などをまとめております。 ・市場概要 ・メタボリックシンドロームの市場動向 ・企業の競争状況、市場シェア ・メタボリックシンドロームの種類別市場規模と予測2016-2027（糖尿病、肥満、高コレステロール血症、リソソーム蓄積症） ・メタボリックシンドロームの用途別市場規模と予測2016-2027（病院、クリニック、その他） ・メタボリックシンドロームの北米市場規模2016-2027（アメリカ、カナダ） ・メタボリックシンドロームの欧州市場規模2016-2027（ドイツ、フランス、イギリス等） ・メタボリックシンドロームのアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・メタボリックシンドロームの中南米市場規模2016-2027（メキシコ、ブラジル） ・メタボリックシンドロームの中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Novo Nordisk、Sanofi、Merck、AstraZeneca、Eli Lily、AbbVie、Actelion Pharmaceuticals、Adocia、Aegerion Pharmaceuticals、Akros Pharma、Alnylam Pharmaceuticals、Amarin、nAmgen、Amicus Therapeutics、Arbutus Biopharma） ・結論

Metabolic syndrome is a cluster of conditions — increased blood pressure, high blood sugar, excess body fat around the waist, and abnormal cholesterol or triglyceride levels — that occur together, increasing your risk of heart disease, stroke and diabetes.
One of the upcoming trends gaining traction in the market is the increasing focus on oral insulin therapies. Till now, insulin injections were mostly administered through subcutaneous tissues, but this route of application is associated with risk of infection and hypersensitivity reactions, emboli, high cost, and injection site pain. Also, several needle-phobic individuals hesitate to adopt this route of administration. This paved the way for extensive research in the development of oral insulin. The oral form of insulin prevents the unpleasantness of insulin injections and other complications associated with the existing therapies. Moreover, oral administration of insulin ensures increased patient comfort and compliance, reduced risk of infection, simpler application, and is cost-effective.

Market Analysis and Insights: Global Metabolic Syndrome Market
The global Metabolic Syndrome market size is projected to reach US$ 34940 million by 2027, from US$ 23890 million in 2020, at a CAGR of 5.1% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Metabolic Syndrome market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Metabolic Syndrome market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Metabolic Syndrome market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Metabolic Syndrome market.

Global Metabolic Syndrome Scope and Market Size
Metabolic Syndrome market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Metabolic Syndrome market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Diabetes
Obesity
Hypercholesterolemia
Lysosomal storage diseases

Segment by Application
Hospital
Clinic
Others

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Novo Nordisk
Sanofi
Merck
AstraZeneca
Eli Lily
AbbVie
Actelion Pharmaceuticals
Adocia
Aegerion Pharmaceuticals
Akros Pharma
Alnylam Pharmaceuticals
Amarin
nAmgen
Amicus Therapeutics
Arbutus Biopharma

レポート目次

---

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Metabolic Syndrome Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Diabetes
1.2.3 Obesity
1.2.4 Hypercholesterolemia
1.2.5 Lysosomal storage diseases
1.3 Market by Application
1.3.1 Global Metabolic Syndrome Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Metabolic Syndrome Market Perspective (2016-2027)
2.2 Metabolic Syndrome Growth Trends by Regions
2.2.1 Metabolic Syndrome Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Metabolic Syndrome Historic Market Share by Regions (2016-2021)
2.2.3 Metabolic Syndrome Forecasted Market Size by Regions (2022-2027)
2.3 Metabolic Syndrome Industry Dynamic
2.3.1 Metabolic Syndrome Market Trends
2.3.2 Metabolic Syndrome Market Drivers
2.3.3 Metabolic Syndrome Market Challenges
2.3.4 Metabolic Syndrome Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Metabolic Syndrome Players by Revenue
3.1.1 Global Top Metabolic Syndrome Players by Revenue (2016-2021)
3.1.2 Global Metabolic Syndrome Revenue Market Share by Players (2016-2021)
3.2 Global Metabolic Syndrome Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Metabolic Syndrome Revenue
3.4 Global Metabolic Syndrome Market Concentration Ratio
3.4.1 Global Metabolic Syndrome Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Metabolic Syndrome Revenue in 2020
3.5 Metabolic Syndrome Key Players Head office and Area Served
3.6 Key Players Metabolic Syndrome Product Solution and Service
3.7 Date of Enter into Metabolic Syndrome Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Metabolic Syndrome Breakdown Data by Type
4.1 Global Metabolic Syndrome Historic Market Size by Type (2016-2021)
4.2 Global Metabolic Syndrome Forecasted Market Size by Type (2022-2027)

5 Metabolic Syndrome Breakdown Data by Application
5.1 Global Metabolic Syndrome Historic Market Size by Application (2016-2021)
5.2 Global Metabolic Syndrome Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Metabolic Syndrome Market Size (2016-2027)
6.2 North America Metabolic Syndrome Market Size by Type
6.2.1 North America Metabolic Syndrome Market Size by Type (2016-2021)
6.2.2 North America Metabolic Syndrome Market Size by Type (2022-2027)
6.2.3 North America Metabolic Syndrome Market Size by Type (2016-2027)
6.3 North America Metabolic Syndrome Market Size by Application
6.3.1 North America Metabolic Syndrome Market Size by Application (2016-2021)
6.3.2 North America Metabolic Syndrome Market Size by Application (2022-2027)
6.3.3 North America Metabolic Syndrome Market Size by Application (2016-2027)
6.4 North America Metabolic Syndrome Market Size by Country
6.4.1 North America Metabolic Syndrome Market Size by Country (2016-2021)
6.4.2 North America Metabolic Syndrome Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada

7 Europe
7.1 Europe Metabolic Syndrome Market Size (2016-2027)
7.2 Europe Metabolic Syndrome Market Size by Type
7.2.1 Europe Metabolic Syndrome Market Size by Type (2016-2021)
7.2.2 Europe Metabolic Syndrome Market Size by Type (2022-2027)
7.2.3 Europe Metabolic Syndrome Market Size by Type (2016-2027)
7.3 Europe Metabolic Syndrome Market Size by Application
7.3.1 Europe Metabolic Syndrome Market Size by Application (2016-2021)
7.3.2 Europe Metabolic Syndrome Market Size by Application (2022-2027)
7.3.3 Europe Metabolic Syndrome Market Size by Application (2016-2027)
7.4 Europe Metabolic Syndrome Market Size by Country
7.4.1 Europe Metabolic Syndrome Market Size by Country (2016-2021)
7.4.2 Europe Metabolic Syndrome Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Metabolic Syndrome Market Size (2016-2027)
8.2 Asia-Pacific Metabolic Syndrome Market Size by Type
8.2.1 Asia-Pacific Metabolic Syndrome Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Metabolic Syndrome Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Metabolic Syndrome Market Size by Type (2016-2027)
8.3 Asia-Pacific Metabolic Syndrome Market Size by Application
8.3.1 Asia-Pacific Metabolic Syndrome Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Metabolic Syndrome Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Metabolic Syndrome Market Size by Application (2016-2027)
8.4 Asia-Pacific Metabolic Syndrome Market Size by Region
8.4.1 Asia-Pacific Metabolic Syndrome Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Metabolic Syndrome Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Metabolic Syndrome Market Size (2016-2027)
9.2 Latin America Metabolic Syndrome Market Size by Type
9.2.1 Latin America Metabolic Syndrome Market Size by Type (2016-2021)
9.2.2 Latin America Metabolic Syndrome Market Size by Type (2022-2027)
9.2.3 Latin America Metabolic Syndrome Market Size by Type (2016-2027)
9.3 Latin America Metabolic Syndrome Market Size by Application
9.3.1 Latin America Metabolic Syndrome Market Size by Application (2016-2021)
9.3.2 Latin America Metabolic Syndrome Market Size by Application (2022-2027)
9.3.3 Latin America Metabolic Syndrome Market Size by Application (2016-2027)
9.4 Latin America Metabolic Syndrome Market Size by Country
9.4.1 Latin America Metabolic Syndrome Market Size by Country (2016-2021)
9.4.2 Latin America Metabolic Syndrome Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Metabolic Syndrome Market Size (2016-2027)
10.2 Middle East & Africa Metabolic Syndrome Market Size by Type
10.2.1 Middle East & Africa Metabolic Syndrome Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Metabolic Syndrome Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Metabolic Syndrome Market Size by Type (2016-2027)
10.3 Middle East & Africa Metabolic Syndrome Market Size by Application
10.3.1 Middle East & Africa Metabolic Syndrome Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Metabolic Syndrome Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Metabolic Syndrome Market Size by Application (2016-2027)
10.4 Middle East & Africa Metabolic Syndrome Market Size by Country
10.4.1 Middle East & Africa Metabolic Syndrome Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Metabolic Syndrome Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Novo Nordisk
11.1.1 Novo Nordisk Company Details
11.1.2 Novo Nordisk Business Overview
11.1.3 Novo Nordisk Metabolic Syndrome Introduction
11.1.4 Novo Nordisk Revenue in Metabolic Syndrome Business (2016-2021)
11.1.5 Novo Nordisk Recent Development
11.2 Sanofi
11.2.1 Sanofi Company Details
11.2.2 Sanofi Business Overview
11.2.3 Sanofi Metabolic Syndrome Introduction
11.2.4 Sanofi Revenue in Metabolic Syndrome Business (2016-2021)
11.2.5 Sanofi Recent Development
11.3 Merck
11.3.1 Merck Company Details
11.3.2 Merck Business Overview
11.3.3 Merck Metabolic Syndrome Introduction
11.3.4 Merck Revenue in Metabolic Syndrome Business (2016-2021)
11.3.5 Merck Recent Development
11.4 AstraZeneca
11.4.1 AstraZeneca Company Details
11.4.2 AstraZeneca Business Overview
11.4.3 AstraZeneca Metabolic Syndrome Introduction
11.4.4 AstraZeneca Revenue in Metabolic Syndrome Business (2016-2021)
11.4.5 AstraZeneca Recent Development
11.5 Eli Lily
11.5.1 Eli Lily Company Details
11.5.2 Eli Lily Business Overview
11.5.3 Eli Lily Metabolic Syndrome Introduction
11.5.4 Eli Lily Revenue in Metabolic Syndrome Business (2016-2021)
11.5.5 Eli Lily Recent Development
11.6 AbbVie
11.6.1 AbbVie Company Details
11.6.2 AbbVie Business Overview
11.6.3 AbbVie Metabolic Syndrome Introduction
11.6.4 AbbVie Revenue in Metabolic Syndrome Business (2016-2021)
11.6.5 AbbVie Recent Development
11.7 Actelion Pharmaceuticals
11.7.1 Actelion Pharmaceuticals Company Details
11.7.2 Actelion Pharmaceuticals Business Overview
11.7.3 Actelion Pharmaceuticals Metabolic Syndrome Introduction
11.7.4 Actelion Pharmaceuticals Revenue in Metabolic Syndrome Business (2016-2021)
11.7.5 Actelion Pharmaceuticals Recent Development
11.8 Adocia
11.8.1 Adocia Company Details
11.8.2 Adocia Business Overview
11.8.3 Adocia Metabolic Syndrome Introduction
11.8.4 Adocia Revenue in Metabolic Syndrome Business (2016-2021)
11.8.5 Adocia Recent Development
11.9 Aegerion Pharmaceuticals
11.9.1 Aegerion Pharmaceuticals Company Details
11.9.2 Aegerion Pharmaceuticals Business Overview
11.9.3 Aegerion Pharmaceuticals Metabolic Syndrome Introduction
11.9.4 Aegerion Pharmaceuticals Revenue in Metabolic Syndrome Business (2016-2021)
11.9.5 Aegerion Pharmaceuticals Recent Development
11.10 Akros Pharma
11.10.1 Akros Pharma Company Details
11.10.2 Akros Pharma Business Overview
11.10.3 Akros Pharma Metabolic Syndrome Introduction
11.10.4 Akros Pharma Revenue in Metabolic Syndrome Business (2016-2021)
11.10.5 Akros Pharma Recent Development
11.11 Alnylam Pharmaceuticals
11.11.1 Alnylam Pharmaceuticals Company Details
11.11.2 Alnylam Pharmaceuticals Business Overview
11.11.3 Alnylam Pharmaceuticals Metabolic Syndrome Introduction
11.11.4 Alnylam Pharmaceuticals Revenue in Metabolic Syndrome Business (2016-2021)
11.11.5 Alnylam Pharmaceuticals Recent Development
11.12 Amarin
11.12.1 Amarin Company Details
11.12.2 Amarin Business Overview
11.12.3 Amarin Metabolic Syndrome Introduction
11.12.4 Amarin Revenue in Metabolic Syndrome Business (2016-2021)
11.12.5 Amarin Recent Development
11.13 nAmgen
11.13.1 nAmgen Company Details
11.13.2 nAmgen Business Overview
11.13.3 nAmgen Metabolic Syndrome Introduction
11.13.4 nAmgen Revenue in Metabolic Syndrome Business (2016-2021)
11.13.5 nAmgen Recent Development
11.14 Amicus Therapeutics
11.14.1 Amicus Therapeutics Company Details
11.14.2 Amicus Therapeutics Business Overview
11.14.3 Amicus Therapeutics Metabolic Syndrome Introduction
11.14.4 Amicus Therapeutics Revenue in Metabolic Syndrome Business (2016-2021)
11.14.5 Amicus Therapeutics Recent Development
11.15 Arbutus Biopharma
11.15.1 Arbutus Biopharma Company Details
11.15.2 Arbutus Biopharma Business Overview
11.15.3 Arbutus Biopharma Metabolic Syndrome Introduction
11.15.4 Arbutus Biopharma Revenue in Metabolic Syndrome Business (2016-2021)
11.15.5 Arbutus Biopharma Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Metabolic Syndrome Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Diabetes
Table 3. Key Players of Obesity
Table 4. Key Players of Hypercholesterolemia
Table 5. Key Players of Lysosomal storage diseases
Table 6. Global Metabolic Syndrome Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 7. Global Metabolic Syndrome Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 8. Global Metabolic Syndrome Market Size by Regions (2016-2021) & (US$ Million)
Table 9. Global Metabolic Syndrome Market Share by Regions (2016-2021)
Table 10. Global Metabolic Syndrome Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 11. Global Metabolic Syndrome Market Share by Regions (2022-2027)
Table 12. Metabolic Syndrome Market Trends
Table 13. Metabolic Syndrome Market Drivers
Table 14. Metabolic Syndrome Market Challenges
Table 15. Metabolic Syndrome Market Restraints
Table 16. Global Metabolic Syndrome Revenue by Players (2016-2021) & (US$ Million)
Table 17. Global Metabolic Syndrome Market Share by Players (2016-2021)
Table 18. Global Top Metabolic Syndrome Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Metabolic Syndrome as of 2020)
Table 19. Ranking of Global Top Metabolic Syndrome Companies by Revenue (US$ Million) in 2020
Table 20. Global 5 Largest Players Market Share by Metabolic Syndrome Revenue (CR5 and HHI) & (2016-2021)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Metabolic Syndrome Product Solution and Service
Table 23. Date of Enter into Metabolic Syndrome Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Metabolic Syndrome Market Size by Type (2016-2021) (US$ Million)
Table 26. Global Metabolic Syndrome Revenue Market Share by Type (2016-2021)
Table 27. Global Metabolic Syndrome Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 28. Global Metabolic Syndrome Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 29. Global Metabolic Syndrome Market Size Share by Application (2016-2021) & (US$ Million)
Table 30. Global Metabolic Syndrome Revenue Market Share by Application (2016-2021)
Table 31. Global Metabolic Syndrome Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 32. Global Metabolic Syndrome Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 33. North America Metabolic Syndrome Market Size by Type (2016-2021) (US$ Million)
Table 34. North America Metabolic Syndrome Market Size by Type (2022-2027) & (US$ Million)
Table 35. North America Metabolic Syndrome Market Size by Application (2016-2021) (US$ Million)
Table 36. North America Metabolic Syndrome Market Size by Application (2022-2027) & (US$ Million)
Table 37. North America Metabolic Syndrome Market Size by Country (2016-2021) & (US$ Million)
Table 38. North America Metabolic Syndrome Market Size by Country (2022-2027) & (US$ Million)
Table 39. Europe Metabolic Syndrome Market Size by Type (2016-2021) (US$ Million)
Table 40. Europe Metabolic Syndrome Market Size by Type (2022-2027) & (US$ Million)
Table 41. Europe Metabolic Syndrome Market Size by Application (2016-2021) (US$ Million)
Table 42. Europe Metabolic Syndrome Market Size by Application (2022-2027) & (US$ Million)
Table 43. Europe Metabolic Syndrome Market Size by Country (2016-2021) & (US$ Million)
Table 44. Europe Metabolic Syndrome Market Size by Country (2022-2027) & (US$ Million)
Table 45. Asia-Pacific Metabolic Syndrome Market Size by Type (2016-2021) (US$ Million)
Table 46. Asia-Pacific Metabolic Syndrome Market Size by Type (2022-2027) & (US$ Million)
Table 47. Asia-Pacific Metabolic Syndrome Market Size by Application (2016-2021) (US$ Million)
Table 48. Asia-Pacific Metabolic Syndrome Market Size by Application (2022-2027) & (US$ Million)
Table 49. Asia-Pacific Metabolic Syndrome Market Size by Region (2016-2021) & (US$ Million)
Table 50. Asia-Pacific Metabolic Syndrome Market Size by Region (2022-2027) & (US$ Million)
Table 51. Latin America Metabolic Syndrome Market Size by Type (2016-2021) (US$ Million)
Table 52. Latin America Metabolic Syndrome Market Size by Type (2022-2027) & (US$ Million)
Table 53. Latin America Metabolic Syndrome Market Size by Application (2016-2021) (US$ Million)
Table 54. Latin America Metabolic Syndrome Market Size by Application (2022-2027) & (US$ Million)
Table 55. Latin America Metabolic Syndrome Market Size by Country (2016-2021) & (US$ Million)
Table 56. Latin America Metabolic Syndrome Market Size by Country (2022-2027) & (US$ Million)
Table 57. Middle East & Africa Metabolic Syndrome Market Size by Type (2016-2021) (US$ Million)
Table 58. Middle East & Africa Metabolic Syndrome Market Size by Type (2022-2027) & (US$ Million)
Table 59. Middle East & Africa Metabolic Syndrome Market Size by Application (2016-2021) (US$ Million)
Table 60. Middle East & Africa Metabolic Syndrome Market Size by Application (2022-2027) & (US$ Million)
Table 61. Middle East & Africa Metabolic Syndrome Market Size by Country (2016-2021) & (US$ Million)
Table 62. Middle East & Africa Metabolic Syndrome Market Size by Country (2022-2027) & (US$ Million)
Table 63. Novo Nordisk Company Details
Table 64. Novo Nordisk Business Overview
Table 65. Novo Nordisk Metabolic Syndrome Product
Table 66. Novo Nordisk Revenue in Metabolic Syndrome Business (2016-2021) & (US$ Million)
Table 67. Novo Nordisk Recent Development
Table 68. Sanofi Company Details
Table 69. Sanofi Business Overview
Table 70. Sanofi Metabolic Syndrome Product
Table 71. Sanofi Revenue in Metabolic Syndrome Business (2016-2021) & (US$ Million)
Table 72. Sanofi Recent Development
Table 73. Merck Company Details
Table 74. Merck Business Overview
Table 75. Merck Metabolic Syndrome Product
Table 76. Merck Revenue in Metabolic Syndrome Business (2016-2021) & (US$ Million)
Table 77. Merck Recent Development
Table 78. AstraZeneca Company Details
Table 79. AstraZeneca Business Overview
Table 80. AstraZeneca Metabolic Syndrome Product
Table 81. AstraZeneca Revenue in Metabolic Syndrome Business (2016-2021) & (US$ Million)
Table 82. AstraZeneca Recent Development
Table 83. Eli Lily Company Details
Table 84. Eli Lily Business Overview
Table 85. Eli Lily Metabolic Syndrome Product
Table 86. Eli Lily Revenue in Metabolic Syndrome Business (2016-2021) & (US$ Million)
Table 87. Eli Lily Recent Development
Table 88. AbbVie Company Details
Table 89. AbbVie Business Overview
Table 90. AbbVie Metabolic Syndrome Product
Table 91. AbbVie Revenue in Metabolic Syndrome Business (2016-2021) & (US$ Million)
Table 92. AbbVie Recent Development
Table 93. Actelion Pharmaceuticals Company Details
Table 94. Actelion Pharmaceuticals Business Overview
Table 95. Actelion Pharmaceuticals Metabolic Syndrome Product
Table 96. Actelion Pharmaceuticals Revenue in Metabolic Syndrome Business (2016-2021) & (US$ Million)
Table 97. Actelion Pharmaceuticals Recent Development
Table 98. Adocia Company Details
Table 99. Adocia Business Overview
Table 100. Adocia Revenue in Metabolic Syndrome Business (2016-2021) & (US$ Million)
Table 101. Adocia Recent Development
Table 102. Aegerion Pharmaceuticals Company Details
Table 103. Aegerion Pharmaceuticals Business Overview
Table 104. Aegerion Pharmaceuticals Metabolic Syndrome Product
Table 105. Aegerion Pharmaceuticals Revenue in Metabolic Syndrome Business (2016-2021) & (US$ Million)
Table 106. Aegerion Pharmaceuticals Recent Development
Table 107. Akros Pharma Company Details
Table 108. Akros Pharma Business Overview
Table 109. Akros Pharma Metabolic Syndrome Product
Table 110. Akros Pharma Revenue in Metabolic Syndrome Business (2016-2021) & (US$ Million)
Table 111. Akros Pharma Recent Development
Table 112. Alnylam Pharmaceuticals Company Details
Table 113. Alnylam Pharmaceuticals Business Overview
Table 114. Alnylam Pharmaceuticals Metabolic Syndrome Product
Table 115. Alnylam Pharmaceuticals Revenue in Metabolic Syndrome Business (2016-2021) & (US$ Million)
Table 116. Alnylam Pharmaceuticals Recent Development
Table 117. Amarin Company Details
Table 118. Amarin Business Overview
Table 119. Amarin Metabolic Syndrome Product
Table 120. Amarin Revenue in Metabolic Syndrome Business (2016-2021) & (US$ Million)
Table 121. Amarin Recent Development
Table 122. nAmgen Company Details
Table 123. nAmgen Business Overview
Table 124. nAmgen Metabolic Syndrome Product
Table 125. nAmgen Revenue in Metabolic Syndrome Business (2016-2021) & (US$ Million)
Table 126. nAmgen Recent Development
Table 127. Amicus Therapeutics Company Details
Table 128. Amicus Therapeutics Business Overview
Table 129. Amicus Therapeutics Metabolic Syndrome Product
Table 130. Amicus Therapeutics Revenue in Metabolic Syndrome Business (2016-2021) & (US$ Million)
Table 131. Amicus Therapeutics Recent Development
Table 132. Arbutus Biopharma Company Details
Table 133. Arbutus Biopharma Business Overview
Table 134. Arbutus Biopharma Metabolic Syndrome Product
Table 135. Arbutus Biopharma Revenue in Metabolic Syndrome Business (2016-2021) & (US$ Million)
Table 136. Arbutus Biopharma Recent Development
Table 137. Research Programs/Design for This Report
Table 138. Key Data Information from Secondary Sources
Table 139. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Metabolic Syndrome Market Share by Type: 2020 VS 2027
Figure 2. Diabetes Features
Figure 3. Obesity Features
Figure 4. Hypercholesterolemia Features
Figure 5. Lysosomal storage diseases Features
Figure 6. Global Metabolic Syndrome Market Share by Application: 2020 VS 2027
Figure 7. Hospital Case Studies
Figure 8. Clinic Case Studies
Figure 9. Others Case Studies
Figure 10. Metabolic Syndrome Report Years Considered
Figure 11. Global Metabolic Syndrome Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 12. Global Metabolic Syndrome Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 13. Global Metabolic Syndrome Market Share by Regions: 2020 VS 2027
Figure 14. Global Metabolic Syndrome Market Share by Regions (2022-2027)
Figure 15. Global Metabolic Syndrome Market Share by Players in 2020
Figure 16. Global Top Metabolic Syndrome Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Metabolic Syndrome as of 2020
Figure 17. The Top 10 and 5 Players Market Share by Metabolic Syndrome Revenue in 2020
Figure 18. Global Metabolic Syndrome Revenue Market Share by Type (2016-2021)
Figure 19. Global Metabolic Syndrome Revenue Market Share by Type (2022-2027)
Figure 20. North America Metabolic Syndrome Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 21. North America Metabolic Syndrome Market Share by Type (2016-2027)
Figure 22. North America Metabolic Syndrome Market Share by Application (2016-2027)
Figure 23. North America Metabolic Syndrome Market Share by Country (2016-2027)
Figure 24. United States Metabolic Syndrome Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. Canada Metabolic Syndrome Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Europe Metabolic Syndrome Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 27. Europe Metabolic Syndrome Market Share by Type (2016-2027)
Figure 28. Europe Metabolic Syndrome Market Share by Application (2016-2027)
Figure 29. Europe Metabolic Syndrome Market Share by Country (2016-2027)
Figure 30. Germany Metabolic Syndrome Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. France Metabolic Syndrome Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. U.K. Metabolic Syndrome Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Italy Metabolic Syndrome Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Russia Metabolic Syndrome Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Nordic Metabolic Syndrome Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Asia-Pacific Metabolic Syndrome Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Asia-Pacific Metabolic Syndrome Market Share by Type (2016-2027)
Figure 38. Asia-Pacific Metabolic Syndrome Market Share by Application (2016-2027)
Figure 39. Asia-Pacific Metabolic Syndrome Market Share by Region (2016-2027)
Figure 40. China Metabolic Syndrome Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. Japan Metabolic Syndrome Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. South Korea Metabolic Syndrome Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. Southeast Asia Metabolic Syndrome Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. India Metabolic Syndrome Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Australia Metabolic Syndrome Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Latin America Metabolic Syndrome Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. Latin America Metabolic Syndrome Market Share by Type (2016-2027)
Figure 48. Latin America Metabolic Syndrome Market Share by Application (2016-2027)
Figure 49. Latin America Metabolic Syndrome Market Share by Country (2016-2027)
Figure 50. Mexico Metabolic Syndrome Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Brazil Metabolic Syndrome Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Middle East & Africa Metabolic Syndrome Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 53. Middle East & Africa Metabolic Syndrome Market Share by Type (2016-2027)
Figure 54. Middle East & Africa Metabolic Syndrome Market Share by Application (2016-2027)
Figure 55. Middle East & Africa Metabolic Syndrome Market Share by Country (2016-2027)
Figure 56. Turkey Metabolic Syndrome Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. Saudi Arabia Metabolic Syndrome Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. UAE Metabolic Syndrome Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 59. Novo Nordisk Revenue Growth Rate in Metabolic Syndrome Business (2016-2021)
Figure 60. Sanofi Revenue Growth Rate in Metabolic Syndrome Business (2016-2021)
Figure 61. Merck Revenue Growth Rate in Metabolic Syndrome Business (2016-2021)
Figure 62. AstraZeneca Revenue Growth Rate in Metabolic Syndrome Business (2016-2021)
Figure 63. Eli Lily Revenue Growth Rate in Metabolic Syndrome Business (2016-2021)
Figure 64. AbbVie Revenue Growth Rate in Metabolic Syndrome Business (2016-2021)
Figure 65. Actelion Pharmaceuticals Revenue Growth Rate in Metabolic Syndrome Business (2016-2021)
Figure 66. Adocia Revenue Growth Rate in Metabolic Syndrome Business (2016-2021)
Figure 67. Aegerion Pharmaceuticals Revenue Growth Rate in Metabolic Syndrome Business (2016-2021)
Figure 68. Akros Pharma Revenue Growth Rate in Metabolic Syndrome Business (2016-2021)
Figure 69. Alnylam Pharmaceuticals Revenue Growth Rate in Metabolic Syndrome Business (2016-2021)
Figure 70. Amarin Revenue Growth Rate in Metabolic Syndrome Business (2016-2021)
Figure 71. nAmgen Revenue Growth Rate in Metabolic Syndrome Business (2016-2021)
Figure 72. Amicus Therapeutics Revenue Growth Rate in Metabolic Syndrome Business (2016-2021)
Figure 73. Arbutus Biopharma Revenue Growth Rate in Metabolic Syndrome Business (2016-2021)
Figure 74. Bottom-up and Top-down Approaches for This Report
Figure 75. Data Triangulation
Figure 76. Key Executives Interviewed

---